Core Insights - Alterity Therapeutics is a biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, particularly Parkinson's disease and related disorders [2][4] - The company will present a corporate update at the Biotech Showcase on September 3, 2025, in Australia and September 2, 2025, in the United States [1][2] Company Overview - Alterity Therapeutics is a clinical-stage biotechnology firm based in Melbourne, Australia, and San Francisco, California, dedicated to creating therapies for neurodegenerative diseases [2] - The company has shown clinically meaningful efficacy for its lead asset, ATH434, in a Phase 2 clinical trial for Multiple System Atrophy (MSA), a rare and rapidly progressive Parkinsonian disorder [2] - ATH434 has recently reported positive data in an open-label Phase 2 clinical trial for advanced MSA [2] - Alterity has a broad drug discovery platform that generates patentable chemical compounds aimed at treating the underlying pathology of neurological diseases [2]